

EVIDENCE-BASED PRACTICE RECOMMENDATIONS

Hepatic Failure: An Evidence-Based Approach In The Emergency Department

Bailey C, Hern HG Jr. April 2010, Volume 12; Number 4

This issue of Emergency Medicine Practice focuses on the management of acute liver failure and the acutely symptomatic cirrhotic patient. For a more detailed discussion of this topic, including figures and tables, clinical pathways, and other considerations not noted here, please see the complete issue on the EB Medicine website at www.ebmedicine.net/topics.

Key Points	Comments
Acute liver failure (ALF) is a rapidly progressive serious illness; prognosis varies with etiology. Acetaminophen intoxication and viral hepatitis are common causes.	Acetaminophen overdose, hepatitis A, "shock liver," and pregnancy-related ALF have the best spontaneous (non-transplanted) survival; ALF due to Wilson disease, hepatitis B, autoimmune hepatitis, Budd-Chiari syndrome, and malignancy fare worse. ^{8,12}
Liver failure is manifested by characteristic laboratory tests including evidence of hepatocellular injury, cholestasis, coagulopathy, and hyperammonemia.	While the correlation of ammonia with degree of encephalopathy is controversial, it may be useful in the workup of undifferentiated encephalopathy. The AASLD position paper on the management of acute liver failure recommends its inclusion in the routine laboratory analysis of these patients. ⁴⁶
Acute liver failure patients may develop hemodynamic instability, cerebral edema, seizures, and hepatorenal syndrome. Reassess vital signs and mental status frequently.	Intracranial hypertension (IH) (as appreciated via neurological signs) should be managed with head-of-bed elevation (30°) and mannitol bolus (0.5-1g/kg); its use has been shown to decrease intracranial pressure and improve survival in ALF patients. ⁶⁴ Hyponatremia (Na 145-155), produced via administration of 30% hypertonic saline, may prevent development of IH. ⁶⁷
Patients with refractory ascites are susceptible to spontaneous bacterial peritonitis (SBP); ascitic fluid should be sent for analysis during therapeutic paracentesis.	While recent analyses of asymptomatic patients undergoing outpatient routine paracentesis have shown a low rate (0-3%) of occult SBP, ^{97,98} analysis of serial samples from inpatients (who may be more similar to a symptomatic emergency department population) demonstrated a much higher rate (21%). ⁹⁹
Patients with cirrhosis and ascites with clinical SBP (fever, leukocytosis, abdominal pain) but < 250 cells/mm ³ should be treated until culture results are known. Antibiotic regimens include cefotaxime (2g IV q8h), ampicillin 2g IV q4h combined with tobramycin 1.75 mg/kg q8 hr, or oral ofloxacin (400 mg bid) for less severe illness in patients who can take PO.	While 1 older study suggests that cefotaxime is superior to ampicillin/tobramycin, ¹⁰⁵ a 2001 Cochrane Review concluded that there was insufficient evidence to support a particular antibiotic regimen, based on 9 available randomized controlled trials comparing antibiotic regimens (no placebo trials) for SBP. ¹⁰⁶
Variceal hemorrhage should be managed with hemodynamic support, vasoactive agents, and endoscopy. Medical therapy regimens in the US include octreotide (50 µg bolus then 60 µg/hr) and vasopressin (0.2-0.4 units/min) accompanied by IV nitroglycerin (starting dose 40 µg/min) to counteract ischemic effects.	A Cochrane meta-analysis of the effects of somatostatin analogues did not demonstrate a mortality benefit, but there was a reduced failure of initial hemostasis and a slightly decreased amount of blood transfused. ¹¹³ A Cochrane meta-analysis of 15 RCTs comparing all types of medical therapy with endoscopic sclerotherapy demonstrated that sclerotherapy was not superior to medical therapy on a variety of outcomes including mortality for initial treatment of variceal hemorrhage. ¹¹⁴

See reverse side for reference citations.

REFERENCES

These references are excerpted from the original manuscript. For additional references and information on this topic, see the full text article at ebmedicine.net.

8. Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. *Am J Gastroenterol*. 2007;102:2086-2102. **(Evidence-based practice guideline)**
12. Chu CM, Sheen IS, Liaw YF. The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. *Gastroenterology*. 1994;107:189-195. **(Nonrandomized cohort study; 62 patients)**
46. Harrison PM, O'Grady JG, Keays RT, et al. Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. *BMJ*. 1990;301:964-966. **(Retrospective study; 150 patients)**
64. Als-Nielsen B, Gluud LL, Gluud C. Dopaminergic agonists for hepatic encephalopathy. *Cochrane Database Syst Rev*. 2004:CD003047. **(Meta-analysis of 5 randomized controlled trials)**
67. Canalese J, Gimson AE, Davis C, Mellon PJ, Davis M, Williams R. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. *Gut*. 1982;23:625-629. **(Randomized, controlled trial; 44 ALF patients)**
97. Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. *J Hepatol*. 2007;47:499-505. **(Unblinded randomized, controlled trial; 22 HRS patients)**
98. Sharma P, Kumar A, Sharma BC, et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. *Am J Gastroenterol*. 2008;103:1689-1697. **(Unblinded randomized, controlled trial; 40 HRS patients)**
99. Umgelter A, Reindl W, Wagner KS, et al. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial. *Crit Care*. 2008;12:R4. **(Prospective, uncontrolled trial; 19 patients with HRS)**
105. Wu SS, Lin OS, Chen YY, et al. Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation. *J Hepatol*. 2001;34:215-221. **(Prospective study; 135 patients with ascites)**
106. Koulaouzidis A, Leontiadis GI, Abdullah M, et al. Leucocyte esterase reagent strips for the diagnosis of spontaneous bacterial peritonitis: a systematic review. *Eur J Gastroenterol Hepatol*. 2008;20:1055-1060. **(Systematic review of 17 prospective trials)**
113. Frossard JL, Spahr L, Queneau PE, et al. Erythromycin intravenous bolus infusion in acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. *Gastroenterology*. 2002;123:17-23. **(Randomized, controlled trial; 105 patients)**
114. Marti-Carvajal AJ, Salanti G, Marti-Carvajal PI. Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases. *Cochrane Database Syst Rev*. 2007:CD004887. **(Systematic review, 1 randomized, controlled trial; 242 patients)**

CLINICAL RECOMMENDATIONS

Designed for use in every-day practice

Use The Evidence-Based Practice Recommendations On The Reverse Side For:

- Discussions with colleagues
- Developing hospital guidelines
- Posting on your bulletin board
- Preparing for the boards
- Storing in your hospital's library
- Teaching residents and medical students

Emergency Medicine Practice subscribers: Are you taking advantage of all your subscription benefits? Visit your free online account at www.ebmedicine.net to search archives, browse clinical resources, take free CME tests, and more.

Not a subscriber to Emergency Medicine Practice? As a subscriber, you'll benefit from evidence-based, clinically relevant, eminently usable diagnostic and treatment recommendations for everyday practice. Plus, you'll receive up to 192 *AMA PRA Category 1 Credits™*; 192 ACEP Category 1 credits; 192 AAFP Prescribed credits; and 192 AOA category 2B CME credits and full online access to our one-of-a-kind online database. Visit www.ebmedicine.net/subscribe or call 1-800-249-5770 to learn more today.

Questions, comments, suggestions?

To write a letter to the editor, email: JagodaMD@ebmedicine.net

For all other questions, contact EB Medicine:

Phone: 1-800-249-5770 or 678-366-7933

Fax: 1-770-500-1316

Address: 5550 Triangle Parkway, Suite 150 / Norcross, GA 30092